Media coverage about RestorGenex (NASDAQ:DFFN) has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RestorGenex earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news articles about the company an impact score of 49.5865169923265 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

RestorGenex (NASDAQ DFFN) traded up $0.11 on Tuesday, hitting $1.47. The stock had a trading volume of 549,500 shares, compared to its average volume of 315,439. RestorGenex has a twelve month low of $1.27 and a twelve month high of $15.50.

COPYRIGHT VIOLATION WARNING: “RestorGenex (DFFN) Given Daily Media Impact Score of 0.21” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at

RestorGenex Company Profile

Diffusion Pharmaceuticals Inc, formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.

Insider Buying and Selling by Quarter for RestorGenex (NASDAQ:DFFN)

Receive News & Ratings for RestorGenex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RestorGenex Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.